Compare Abeona Therapeutics Inc (ABEO) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Gemini Space Station Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Gemini Space Station Inc trades at $4.02 (market cap $517.11M). The key difference: Gemini Space Station Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | GEMI | |
|---|---|---|
Market Cap | $424.33M | $517.11M |
Sector | Health | Technology |
52-Week High | $7.45 | $32.52 |
52-Week Low | $4.17 | $3.90 |
Enterprise Value | $279.23M | $507.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
GEMI trades at $4.09, up 2.76% today, but remains in a bearish technical trend with support and resistance clustered at $4. The company reported a net loss of $582.81 million in 2025, with negative margins and cash flow from operations, while revenue grew to $179.57 million. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May 2026.
The outlook is highly speculative with significant operational losses and legal overhangs, though analyst consensus suggests a $6.33 price target. Investment opportunity hinges on turnaround execution and super app adoption, but risks include persistent unprofitability, competitive pressure, and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
